All In Biotech

Drug Trial Radar · NCT06891040

Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

118

Actual

Start

Apr 28, 2025

Primary completion

Oct 31, 2025

Study completion Nov 4, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, vehicle controlled phase II clinical study

Conditions

  • Atopic Dermatitis

Interventions

  • VC005 Placebo groupDrug

    VC005 Placebo group with Local topical application

  • VC005 groupsDrug

    VC005 group with Local topical application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in EASI(Eczema area and severity index) from baselineTime frame: 8 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences Hospital of Skin Disease

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.